Close menu

November 8th, 2021 | 12:08 CET

BioNTech, Moderna, Cardiol Therapeutics, Valneva: COVID-19, the vaccination chaos is perfect!

  • Biotechnology
Photo credits:

Now the chaos is perfect. According to studies, the preparation from BioNTech/Pfizer is one of the most effective vaccines against the coronavirus. Hundreds of millions of doses have already been administered worldwide. However, the number of COVID infections is currently through the roof. Even those who have been vaccinated twice are likely still not sufficiently protected against infection. There are also unsettling rumors from BioNTech about irregularities in the conduct of studies during the vaccine's approval. Whether it concerns thereby only "rumors" or "provable facts", the capital investors do not care for the time being. They pressed the sell button and thus sent the entire peer group Adhoc into the basement. We take a closer look at the chaos.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , MODERNA INC. DL-_0001 | US60770K1079 , CARDIOL THERAPEUTICS | CA14161Y2006 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNTech and Moderna - Share price collapse due to wild rumors and whistleblowers

    The two top dogs in the vaccine business saw a sell-off on Friday. The reason is that serious allegations have been made against a subcontractor of Pfizer commissioned with clinical studies on the Corona vaccine. As the renowned journal "British Medical Journal" (BMJ) reported regarding an ex-employee of Ventavia, the Company from the US state of Texas is alleged to have falsified data in studies on the vaccine from BioNTech/Pfizer and to have slopped in the tracking of side effects.

    The BMJ report is based largely on testimony from former Ventavia employee Brook Jackson. She was involved in the Company's clinical trials of the Corona vaccine for two weeks before she was fired. Among other things, Jackson, a whistleblower, accuses Ventavia of failing to implement the so-called double-blind procedure involving placebos. The aim of this is to enable the most objective possible evaluation of the study results. Allegedly, the FDA has already been informed about this deficiency but did not want to comment on the matter when asked.

    It also fits into the opaque situation that Moderna announced weak figures last week. The partner company of BionNTech Pfizer is said to have developed its own drug for oral administration against COVID-19. On Friday, there were also rumors about the alleged arrest of Pfizer CEO Albert Bourla in Canada, which quickly turned out to be a false spread.

    But this could not help the prices of BioNTech and Moderna at the end of last week. Both values said goodbye with a decline of more than 20% into the weekend. USD 35 billion shareholder capital dissolved into thin air within 24 hours. If the last analyst estimates are still valid, BioNTech is now trading at a P/E of only 6.5 and Moderna at 11.5. The shares have rarely been this cheap. Nevertheless, we wait and see how the news develops.

    Cardiol Therapeutics - Capital increase for clinical studies

    It happens again and again that rapidly growing companies resort to capital increases with certain price dynamics. At this moment, the medium-term investor realizes that a stock market listing is equivalent to the original idea of financing growth and does not have to be centrally in line with investor interests. So if good prospects often drive up share prices, even irrationally, it is only fitting that a company's founders and board members should seize the opportunity to raise additional equity capital for the Company.

    In Germany, existing shareholders are protected from dilution by the so-called subscription right if they subscribe per the allotted right. In Anglo-Saxon countries, the possibility also exists for larger capital measures with the waiver of the rights of the existing shareholders. In the case of Cardiol Therapeutics Inc., this approach has happened twice now in 2021. Looking at the chart, it is easy to miss the timing because there was a sharp rise in the share price in the run-up to a corporate action each time.

    At least the actions at Cardiol are happening in a very positive corporate development environment. The Canadian Department of Health Canada has granted the Company approval to continue work on its Phase II study to evaluate the safety and tolerability of CardiolRx and its effects on myocardial regeneration in patients with acute myocarditis. This approval follows the release of the investigational new drug (IND) application to initiate this study by the US Food and Drug Administration (FDA), which the Company announced on August 24, 2021.

    Looking at the positive performance of the share since its launch in Germany, the overall valuation is still positive: CRDL shares have gained 11% since January and have raised a total of USD 72 million in new capital. It means that the financing of the promising pipeline is secured until well into 2022. In addition, the Nasdaq listing contributed to significant attention in recent months, causing the share price to explode to over CAD 6 on the Canadian home exchange. This move could be repeated in the coming months if the Company delivers accordingly.

    Valneva - When is the conventional COVID-19 vaccine coming?

    In the heated vaccination debate, reports of allegedly flawed approval processes and recurring rumors about the big commercial winners of the global vaccination campaign are not exactly confidence boosters for many people. The share of the French biotech company Valneva therefore continues to be the focus of interest. Especially in Germany, there is a justified interest in alternatives to the well-known mRNA vaccines due to the restrained vaccination rate. The reemerging situation in the COVID-19 pandemic across Europe is additionally driving the issue.

    Valneva is a French biotech company headquartered in Saint-Herblain. The Company was formed by the merger of France's Vivalis with Austria's Intercell. It develops and markets vaccines against infectious diseases and has manufacturing facilities in Austria, Scotland and Sweden, as well as subsidiaries in France, Canada and the United States. Valneva, with its VLA2001 inactivated vaccine, is certainly seen by many as something of a beacon of hope in the pandemic; prominent soccer player Joshua Kimmich had also recently made a public statement as a wait-and-see candidate.

    Valneva is a highly ambitious "second mover" within the vaccine sector, and the share price jumps back and forth just as volatile with each new announcement. Analytically, the share is not cheap with a capitalization of EUR 1.8 billion and can therefore be described as highly speculative. It will remain a plaything of the current news situation until its approval is granted.

    Investment in bio-pharma stocks is currently characterized by high volatility. With the new infection figures, the fantasy for stock market valuations goes into the next round. The last trading days show that there can be some surprises. Cardiol Therapeutics is doing well with its therapy field in cardiovascular diseases, an issue that costs the lives of 30% of humanity every year.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by André Will-Laudien on June 21st, 2024 | 07:00 CEST

    Biotech: What counts is selection! Bayer, Vidac Pharma, Formycon, and Evotec in focus

    • Biotechnology
    • Pharma
    • Biotech

    The biotech sector has so far been unable to keep pace with the high-tech-heavy NASDAQ. However, there are now signals from the central banks that a turnaround in interest rates is imminent. This is because, on the one hand, the US economy is weakening, and on the other hand, inflationary pressure appears to be easing. With lower interest rates, life science companies can refinance themselves more cheaply. Due to the different dynamics, it is now important to fish out the pearls. We select attractive entry levels.


    Commented by Armin Schulz on June 17th, 2024 | 06:30 CEST

    BioNTech, dynaCERT, Plug Power - A single piece of news can change everything

    • Hydrogen
    • greenhydrogen
    • Biotechnology

    Share prices are characterized by their high volatility and can undergo significant changes in a short space of time. Often, just one piece of company news can completely change investor confidence. Shares that were previously under selling pressure and were avoided can suddenly become very popular and experience considerable price increases. Examples include Lufthansa, whose share price rose significantly with the end of the COVID-19 pandemic. Market sentiment can turn quickly when negative factors disappear. A single piece of positive company news can prompt investors to become more involved again, significantly increasing demand and, consequently, the share price. We have identified three potential turnaround candidates.


    Commented by Armin Schulz on June 10th, 2024 | 07:15 CEST

    Evotec, Vidac Pharma, Bayer - Biotech and Pharma: Opportunities for investors

    • Biotechnology
    • Pharma

    In the constantly evolving pharmaceutical and biotechnology industry landscape, innovative strength and strategic orientation play a decisive role in success. Both established groups and young, up-and-coming companies are competing for market share and scientific breakthroughs. In this context, it is worth taking a closer look at Vidac Pharma, Bayer and Evotec. These companies are pursuing different approaches and strategies to achieve their respective goals. How do they manage to hold their own in a highly dynamic market environment, and what prospects are emerging for the future?